Esperite N.V. (ESP) : Update to the market on the publica-tion of the Annual Report 2018 and The Cell Factory cur-rent configuration.
Amsterdam, The Netherlands – 13 May 2019
Esperite N.V. announced on 30 April 2019 that the publication of the Annual Report 2018 will be delayed. The Company has made significant progress and it is confident in its ability to publish the Annual Report 2018 and Half Year Results 2018 before the end of June 2019.
Esperite N.V. with his subsidiary The Cell Factory wants to confirm that the recent adverse situation does not affect the company’s R&D projects in the field of Exosomes and Micro Vesicules. Esperite N.V. is in full control of the Intellectual Property and Patents related to these projects. The production unit in Niel has faced an adverse situation due to local regulation. The Cell Factory has been put in liquidation due to its negative equity despite the positive cash position which was sufficient to cover the claims of the first ranked creditors and most of the others.
Esperite NV continues the negotiations with the potential investors as it was announced previously and will update as soon as necessary.
ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.
To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar: +31 575 548 998 - firstname.lastname@example.org or visit the websites at www.esperite.com, www.genoma.com and www.cryo-save.com.
This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).
Upcoming Life Sciences Events
- September 2019
- Boston: 9th Annual American Drug Delivery & Formulation Summit
- Malmo: NLS Days 2019
- Boston: Redefining Early Stage Investments (RESI)